Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)Yuankai Shi, Luyao Sun, Xinmin Yu et al.|癌症：英文版|2022Cited by 60